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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S181symptoms (O2 requirement, RR > 24). ES characteristics and
consequences were compared for Maiolino and Spitzer
hybrid criteria (Maiolino criteria w/in 4d of ANC500 rather
than 24 hours of ﬁrst neutrophils) and Mayo Criteria (MC).
Pretransplant characteristics, ASCT complications, and the
dynamics of count recovery were all assessed.
Results: 146 (28%) had ES by MC while 48 (9%) had ES by
Maiolino Criteria. Patients with ES by MC experienced longer
hospital stays and received more IV antibiotics (Table 1).
Patients with ES were more likely to have amyloidosis,
a trend toward a higher pre-apheresis PB CD34+ count
(p¼0.053) and pre-apheresis PB WBC count (p¼0.052);
receive fewer days of G-CSF (P < 0.0001), and undergo
fewer apheresis sessions to meet collection goals (p¼0.012)
with more CD34+/kg collected per apheresis (p¼0.012).
They were also less likely to have undergone
chemomobilization. Too few patients perished within 30
days of ASCT (<1%) for meaningful statistical conclusions,
although, 5 patients died within 30d, 3 of whom ES may
have contributed. Patients with ES had shorter times to
ANC500 and ANC1000 (P < 0.0001) as well as from
WBC500 to ANC1000 (P < 0.0001). Patients on
corticosteroids for other reasons had fewer episodes of ES
(4% vs 29%; RR 0.133; P ¼ .003).
Conclusions: Mayo ES criteria were better able to identify
patients with increased resource utilization. As the rate of ES
was signiﬁcantly less in patients on corticosteroids for
reasons other than ES, it is possible that prophylaxis with low
doses of corticosteroids in patients at high risk of ES may















11 8 <0.0001 10 10 0.28
Days hospitalized 6 0 <0.0001 3 2 0.69
Days before
dismissal home
20 20 0.65 19 20 0.2133
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Multiple myeloma (MM) remains a largely incurable disease
despite recent advances in biologic therapy. Autologous stem
cell transplant (ASCT) is the cornerstone of management yet
morbidity and transplant related mortality (TRM) remain
concerns for patients and physicians alike. Between October
2001 and June 2008, 21 MM patients underwent tandem
ASCT as part of a prospective phase II clinical study. After
initial ASCT, disease response was assessed at post-trans-
plant day 100 (D+100). Patients achieving very good partial
remission (VGPR) were offered maintenance therapy. If
patients achieved partial remission (PR), they were offered
a second autologous transplant (ASCT2) with a novel
conditioning regimen: Continuous IV cyclophosphamide
(CICy) 1500mg/m2/day on day -7 through day -4 followed by
and low dose total body irradiation (ldTBI) given twice dailyat 150 cGy on day -2 and -1. TBI was replaced by melphalan
140 mg/m2 if patients had received prior radiation. Median
duration of neutropenia with CICy/ldTBI was 10 days (range,
8-20). 15 patients (71.4%) developed febrile neutropenia.
After fever, grade 1-2 diarrhea was the most common non-
hematologic adverse event (42.9%). One patient each (4.8%)
developed a limited subdural bleed, pulmonary embolus,
neutropenic colitis, bacterial pneumonia, possible fungal
pneumonia, hemorrhagic cystitis, and septic shock. 19
patients (90.5%) required transfusion support (red blood
cells, platelets, or both) in the post-transplant period. All
patients were alive at D+100 with no treatment related
mortality. Three patients received CICY and melphalan. After
ASCT2, four patients had entered complete remission (CR)
(19.0%), seven achieved VGPR (33.3%), while six (28.6%) had
PR. At 4 years after enrollment of last patient, the median
progression free survival and overall survival was 21 (range,
7-101) and 38 (range, 12-128) months, respectively. In
conclusion, this novel conditioning regimen is safe and
effective alternative to high-dose melphalan, and may be
useful in patients who do not beneﬁt from ﬁrst ASCT using
other conditioning regimens.134
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In autologous hematopoietic stem cell transplantation
(ASCT), G-CSF administered from day +7 until ANC recovery,
expedites ANC recovery and reduces days of hospitalization
by 1-2 days. To determine whether delayed and abbreviated
G-CSF dosage could produce equivalent ANC recovery and
thereby improve cost effectiveness of ASCT for myeloma, we
delayed administration of G-CSF until WBC recovery had
begun and was 0.20/uL. G-CSF so administered was labeled
deferred G-CSF dosing (DGD), Patients in the conventional
dosing group (CGD) received daily doses of 5 mg/kg G-CSF
beginning day +7. The primary and secondary end points are
listed in table-1. The Institutional Review Board approved
retrospective chart analysis
A total of 117 patients with multiple myeloma received
ASCT from January 2005 to September 2012. Of these, 65
patients received DGD and 52 received CGD. Patient, disease,
and transplant-related variables were similar between 2
groups; patients in DGD received a larger dose of CD34+
cells/kg (median 4.49, range¼ 2.49-10.2 vs. median 3.79,
range ¼ 2.61-9.42, p¼ 0.021)
The CGD group received a median of 5 doses of G-CSF,
while the DGD group received, a median of 0 (range 0-5,
P  .0001) G-CSF doses (5mg/kg) when the WBC were
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a median of 158/uL (range 0-1168/uL); 36/65 (55%) patients
in DGD received no G-CSF (at physician's discretion) and
those who received the drug did so starting on day 14
(median) post-transplant (range ¼11d-18d). There was no
difference in the incidence or duration of  grade III muco-
sitis, weight gain, rash or engraftment syndrome between
DGD and CGD groups. However, as shown in Table 1 the CGD
group had signiﬁcantly faster engraftment, abbreviation of
neutropenia, diminished antibiotics use, and shorter hospi-
talization. These effects were independent of CD 34 cell dose.
Primarily because of abbreviated hospital stay, there was
a 17% cost beneﬁt to the use of CGD, supporting the overall
beneﬁt of this treatment regimen for patients with MM who
receive ASCT.Table 1
Characteristics CGD group DGD group P value
Neutrophil Engraftment (days) 12 (11-14) 15 (11-20) <0.0001
Duration of neutropenia 7 (5-9) 10 (6-16) <0.0001
(ANC <500)
Duration of severe neutropenia 6 (4-9) 8 (4-10) <0.0001
(ANC < 100) days
Duration of intravenous antibiotics 5 (3-20) 8 (3-15) 0.016
Duration of hospital stay 17 (14-24) 19 (16-28) <0.0001135
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The Autologous Hematopoietic Stem Cell Transplantation
(AHSCT) is a therapeutic method used in various immuno-
logical, hematological and genetic disorders, which uses
patient's own stem cells collected from peripheral blood
after their (the stem cells) mobilization by granulocyte
colony-stimulating factors (GCS-F), in order to restore the
damaged or defective bone marrow function. Oxidative
stress and antioxidant depletion have been described during
the stages involved in AHSCT. Glutathione peroxidase is an
enzyme responsible for detoxiﬁcation of organic and inor-
ganic peroxides, which participates of enzymatic cellular
antioxidant defense. The aim of the study was to evaluate the
levels of glutathione peroxidase in various stages involving
AHSCT in patients undergoing autologous hematopoietic
stem cell transplantation. Glutathione peroxidase was
determined using the Glutathione Peroxidase Ransel kit
(Randox). We measured glutathione peroxidase levels of
eight patients at different times pre-and post-AHSCT: before
Conditioning Regimen (CR), 24 hours after chemotherapy, 10
days (D +10) and 20 days (D +20) after transplantation. There
was a statistically signiﬁcant difference in levels of gluta-
thione peroxidase after CR comparing to other times, sug-
gesting an increase in oxidative stress after chemotherapy.
According to previous studies, oxidative stress occurs acutely
after high-dose chemotherapy for AHSCT and is apparently
related to late hematological recovery. Thus, it can be sug-
gested the use of glutathione peroxidase levels, and otheroxidative stress parameters as toxicity and grafting markers
after AHSCT.136
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Introduction: Peripheral blood progenitor cell (PBPC)
mobilization with intermediate-dose cyclophosphamide (3-
4 gm/m2) (ID-CY) and G-CSF when compared to low-dose CY
(1-2 gm/m2)-based strategies, has been shown to have
a favorable risk/beneﬁt proﬁle in multiple myeloma (MM)
patients (pts) receiving novel induction therapies. However
the relative efﬁcacy of ID-CY as compared to plerixafor (P) in
PBPC mobilization in MM pts is not known. Herein we
report outcomes of ID-CY/G-CSFmobilization compared to P/
G-CSF mobilization in MM pts treated with novel
inductionregimens.
Methods: This multicenter outcomes study includes 84 pts
who underwent a planned, single autograft within 1-year
of starting induction therapy with novel chemotherapy
agents (thalidomide, lenalidomide, bortezomib). Consecu-
tive pts undergoing mobilization with ID-CY/G-CSF (3-4
gm/m2) (n¼55) at one institution were compared against
consecutive pts receiving plerixafor/G-CSF (0.24 mg/kg)
(n¼29) at a different transplant center. In order to assess
efﬁciency of PBPC mobilization, we evaluated peak
peripheral blood (PB) CD34+ cell counts, CD34+ cell yield
on day1 of collection, total CD34+ cell collection, and total
number of apheresis sessions. Mobilization failure was
deﬁned as failure to collect 2 x106 cells/kg body weight.
All pts with normal renal function received uniform
conditioning with Mel200 (MEL140 if serum creatinine
was 2 mg/dl).
Results: At baseline, the ID-CY and P cohorts were well
balanced. No difference was observed in the use of lenali-
domide (p¼0.3). Compared to P, ID-CY use was associated
with higher median peak PB CD34+ cell count (63/ml vs. 160/
ml, P¼ .01), CD34+ yield on day 1 of collection (6.5 x106/kg vs.
11.7 x106/kg, P ¼ .004), and total CD34+ cell yield (10.5 x106/
kg vs. 24.9 x106/kg, P ¼ .001). Median numbers of apheresis
sessions were 2.2 in each group (p¼0.9). No mobilization
failures were seen in either group. Therewas no difference in
the proportion of pts collecting 5x106/kg CD34+ cells in
either group (93% vs. 96%, P ¼ .6), but more pts in ID-CY
cohort collected 10x106/kg CD34+ cells (55% vs. 78%, P ¼
.02). Neutrophil engraftment was signiﬁcantly faster (9.9
